gabapentin and dronabinol

gabapentin has been researched along with dronabinol in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (35.71)29.6817
2010's8 (57.14)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Elovic, E; Lombard, L; Zafonte, R1
De Vry, J; Jentzsch, KR1
Doupe, M; Esfahani, F; Ethans, K; Galloway, K; Gomori, A; Namaka, M; Torabi, M; Turcotte, D1
Laprevote, V; Rolland, B; Schwan, R; Schwitzer, T; Thome, J1
Hays, LR; Kelly, TH; Lile, JA; Wesley, MJ1
Trojano, M1
Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P1
Atwal, N; Casey, SL; Mitchell, VA; Vaughan, CW1
Alcorn, JL; Hays, LR; Kelly, TH; Lile, JA; Stoops, WW; Wesley, MJ; Westgate, PM1

Reviews

4 review(s) available for gabapentin and dronabinol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Antispasticity medications: uses and limitations of enteral therapy.
    American journal of physical medicine & rehabilitation, 2004, Volume: 83, Issue:10 Suppl

    Topics: 4-Aminopyridine; Acetates; Adrenergic alpha-Agonists; Amines; Baclofen; Benzodiazepines; Cyclohexanecarboxylic Acids; Cyproheptadine; Dantrolene; Dronabinol; Gabapentin; gamma-Aminobutyric Acid; Glycine; Humans; Muscle Relaxants, Central; Muscle Spasticity; Neuroprotective Agents; Piracetam; Serotonin Antagonists

2004
Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety.
    Current pharmaceutical design, 2015, Volume: 21, Issue:23

    Topics: Acetylcysteine; Amines; Cannabidiol; Cyclohexanecarboxylic Acids; Dronabinol; Drug Combinations; Gabapentin; gamma-Aminobutyric Acid; Humans; Inappropriate Prescribing; Marijuana Abuse; Marijuana Smoking; Off-Label Use; Patient Safety; Practice Patterns, Physicians'; Psychotropic Drugs; Risk Assessment; Risk Factors; Treatment Outcome

2015
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:11

    Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diazepam; Dronabinol; Drug Combinations; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Humans; Injections, Spinal; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Phenol

2016

Trials

2 trial(s) available for gabapentin and dronabinol

ArticleYear
Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial.
    Pain medicine (Malden, Mass.), 2015, Volume: 16, Issue:1

    Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Dronabinol; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuralgia; Pain Measurement

2015
Influence of pregabalin maintenance on cannabis effects and related behaviors in daily cannabis users.
    Experimental and clinical psychopharmacology, 2022, Volume: 30, Issue:5

    Topics: Calcium Channels, L-Type; Cannabinoid Receptor Agonists; Cannabinoids; Cannabis; Double-Blind Method; Dronabinol; Female; Gabapentin; Hallucinogens; Humans; Ligands; Male; Marijuana Abuse; Pregabalin

2022

Other Studies

8 other study(ies) available for gabapentin and dronabinol

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat.
    European journal of pharmacology, 2004, Nov-28, Volume: 505, Issue:1-3

    Topics: Alkanesulfonates; Amines; Amitriptyline; Animals; Baclofen; Behavior, Animal; Benzoxazines; Carbamazepine; Cyclohexanecarboxylic Acids; Cyclohexanols; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Gabapentin; gamma-Aminobutyric Acid; Indans; Male; Molecular Structure; Morphine; Morpholines; Naphthalenes; Nitriles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Sulfonic Acids

2004
Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.
    Behavioural pharmacology, 2016, Volume: 27, Issue:2-3 Spec I

    Topics: Amines; Analysis of Variance; Blood Pressure; Body Temperature; Cyclohexanecarboxylic Acids; Discrimination Learning; Dronabinol; Drug Combinations; Excitatory Amino Acid Antagonists; Female; Gabapentin; gamma-Aminobutyric Acid; Heart Rate; Humans; Male; Marijuana Abuse; Outcome Assessment, Health Care; Psychomotor Performance; Surveys and Questionnaires; Visual Analog Scale

2016
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    European neurology, 2016, Volume: 75 Suppl 1

    Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxylic Acids; Dronabinol; Drug Combinations; Drug Therapy, Combination; Female; Gabapentin; gamma-Aminobutyric Acid; Germany; Humans; Italy; Male; Medical Marijuana; Middle Aged; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Observational Studies as Topic; Oral Sprays; Plant Extracts; Pregabalin; Prospective Studies; Treatment Outcome

2016
THC and gabapentin interactions in a mouse neuropathic pain model.
    Neuropharmacology, 2019, Volume: 144

    Topics: Analgesics; Animals; Cold Temperature; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Synergism; Gabapentin; Hyperalgesia; Male; Mice, Inbred C57BL; Motor Activity; Neuralgia; Sciatic Nerve; Time Factors; Touch

2019